Home » Newsletters » BioWorld Science

BioWorld Science

April 21, 2016

View Archived Issues

Johnson & Johnson profiles activities of first quarter 2016

First phase I clinical results for IRX-4204 as potential treatment for PD

Roche reviews pipeline progress of first quarter 2016

Novel ERK1/2 inhibitor ASN-007 shows strong antitumor activity in multiple RAS mutant models

Spectrum's Evomela receives 7 years of orphan drug exclusivity

New model of PMM2-CDG recapitulates human disease in mice

Bristol-Myers Squibb patents NS5B inhibitors

FDA removes clinical hold on Cara Therapeutics' CR-845

N & N Pharmaceuticals begins phase I trial of N-MCT

AbbVie enters 5-year collaboration agreement with University of Chicago

Venclexta available in U.S. through Biologics

AbbVie and Argenx collaborate on anti-GARP antibody candidate ARGX-115

BioMarin reports phase I/II data on BMN-270

Eiger licenses PEGylated interferon lambda-1a rights from Bristol-Myers Squibb

Phase IIb/III study of bimagrumab in sporadic inclusion body myositis misses primary endpoint

Phase I/II trial explores use of SHR-3680 for metastatic castration-resistant prostate cancer

Pluristem enters licensing agreement for placental cell therapy patent

BioMarin updates findings from phase II study of vosoritide in achondroplasia

Boehringer Ingelheim initiates phase I study of anti-CX3CR1 Nanobody from Ablynx alliance

Genticel reports additional 12-month data from phase II trial of GTL-001

Durvalumab plus gefitinib active in NSCLC patients with EGFR mutations

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...